Innocan Pharma Corp (INNO.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 4,988 | 6,822 | 7,006 | 7,796 | 5,401 |
| Cost of Goods | 558 | 631 | 811 | 681 | 992 |
| Gross Profit | 4,430 | 6,191 | 6,195 | 7,115 | 4,409 |
| Operating Expenses | 5,352 | 7,409 | 5,799 | 6,626 | 5,328 |
| Operating Income | -922 | -1,218 | 396 | 489 | -919 |
| Interest Expense | 3 | N/A | 4 | 3 | 3 |
| Other Income | 2,518 | -214 | -501 | -453 | 925 |
| Pre-tax Income | 1,593 | -1,432 | -109 | 33 | 3 |
| Income Tax | -262 | 220 | 206 | 262 | 51 |
| Net Income Continuous | 1,855 | -1,652 | -315 | -229 | -48 |
| Minority Interests | 140 | -295 | -275 | -353 | -66 |
| Net Income | $1,995 | $-1,947 | $-590 | $-582 | $-114 |
| EPS Basic Total Ops | 0.32 | -0.36 | -0.13 | -0.13 | -0.26 |
| EPS Basic Continuous Ops | 0.32 | -0.36 | -0.13 | -0.13 | -0.26 |
| EPS Diluted Total Ops | 0.32 | -0.36 | -0.13 | -0.13 | -0.26 |
| EPS Diluted Continuous Ops | 0.32 | -0.36 | -0.13 | -0.13 | -0.26 |
| EBITDA(a) | $1,608 | $-1,207 | $-96 | $46 | $12 |